What the research found

Anabolic steroids increase heartburn risk through multiple overlapping mechanisms. Exogenous androgens disrupt the normal regulation of gastric acid secretion by interfering with hepatic enzyme systems and directly altering signalling at H2 histamine receptors on stomach parietal cells. Animal studies in testosterone-treated rats have demonstrated measurable changes in stomach acid physiology. The effect appears dose- and potency-dependent: androgens delay ulcer healing, reduce mucosal blood flow, increase acid output, and elevate inflammatory markers in gastric tissue.

A key finding is that the heartburn risk correlates with net androgenicity—the androgenic potency minus estrogenic activity of a given steroid. Non-aromatising androgens (trenbolone, fluoxymesterone, methasterone) carry higher gastric risk, while aromatisable compounds like testosterone and methandienone cause fewer reports of reflux, presumably because estrogen exerts a protective effect on the stomach lining.

Why it matters for you

If you run higher-dose androgens or stack non-aromatising compounds, steroid-induced reflux is a real dose-limiting side effect—not merely uncomfortable but potentially damaging to stomach lining if left untreated. Rather than treating heartburn reactively when it flares, the source recommends starting low-dose H2 antagonists (famotidine or ranitidine, not cimetidine) as baseline prophylaxis during a cycle once reflux symptoms first appear. Bedtime dosing targets the nocturnal acid surge when reflux is most active.

For protocol planning: if you're running a harsh nonaromatising compound, you may need gastroprotection built into your cycle from the start. Conversely, if you're on a testosterone or aromatisable base, reflux may be less of a concern—though individual variation exists. This ties directly to cycle selection and whether your bloat and lipid goals align with choosing an aromatiser.

Caveats

  • Animal-model findings (rat studies) may not directly translate to human gastric physiology or clinical outcomes
  • No human trials cited; mechanisms are inferred from rodent data and pharmacological theory
  • Effect sizes and prevalence in human users are not quantified
  • Recommendation for continuous (rather than as-needed) antacid use is clinical guidance, not derived from controlled trials
  • Individual susceptibility to steroid-induced reflux varies; baseline stomach health, diet, and age all modulate risk
  • Long-term safety of continuous H2 antagonist use during steroid cycles is not addressed